Immune cell freezing medium and use method thereof

Abstract

The invention discloses an immune cell freezing medium and a use method thereof. The immune cell freezing medium comprises a freezing agent A and a freezing agent B, the freezing agent A comprises human serum albumin, hydroxyethyl starch, a basal culture medium and IL-2; the volume fraction of the human serum albumin is 60-70%; the volume fraction of the basic culture medium is 20-30%; the mass fraction of the hydroxyethyl starch is 3m / v to 5m / v; the concentration of the IL-2 is 1000U / ml to 2000U / ml; the freezing agent B comprises dimethyl sulfoxide, trehalose, dextran and Ectoin, and the volume fraction of the dimethyl sulfoxide is 5%-10%; the volume fraction of the trehalose is 20%-30%; the volume fraction of dextran is 60%-70%; the mass fraction of Ectoine is 2%. According to the technical scheme provided by the invention, the unexpected cryopreservation effect is achieved after traditional clinical medicines and chemical reagents are combined and separately used, so that the activity of the recovered immune cells is obviously enhanced, the recovery proliferation cycle is shortened, and the killing toxicity and factor secretion ability are quickly recovered.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to an immune cell cryopreservation solution and a method for using the same. Background technique [0002] Tumor immunotherapy is a method of using biotechnology and biological agents to culture and expand immune cells collected from patients in vitro and then infuse them back into the patient's body to stimulate and enhance the body's autoimmune function, so as to achieve the purpose of treating tumors. Biological immunotherapy is the fourth largest tumor treatment technology after surgery, radiotherapy and chemotherapy. At present, adoptive immunotherapy has become one of the main methods of tumor immunotherapy. Adoptive cellular immunotherapy ACT mainly includes non-specific therapy LAK, CIK, DC, NK and specific TIL, TCR, CAR. [0003] It is well known that the immune cell culture cycle is very short, generally ranging from 14 to 21 days. With the extension of the culture t...

AI Technical Summary

Problems solved by technology

Conventional cryopreservation solutions are composed of one or several components such as high-concentration DMSO, autologous plasma, serum, albumin, and chemical reagents. These cryopreservation solutions have the characteristics of poor cryopreservation effect, loss of cell biological activity, high risk of clinical application, and high cost. , and the cells often need a buffer period of 3 to 4 days to recover their proliferation ability and biological function after recovery, which cannot really meet the cryopreservation requirements of intermediate products of immune cells

Images